ReviewHuman molecular genetics2016
Pathway and network-based strategies to translate genetic discoveries into effective therapies.
Review in Human molecular genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes.NPJ drug discovery · 2026Article
- Innovative horizons: harnessing drug repositioning for targeted therapeutics in colorectal cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Single-cell-led drug repurposing for Alzheimer's disease.Scientific reports · 2023Article
- Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.Current oncology (Toronto, Ont.) · 2023Review
- Informatics on Drug Repurposing for Breast Cancer.Drug design, development and therapy · 2023Review
- Current trends and future prospects of drug repositioning in gastrointestinal oncology.Frontiers in pharmacology · 2023Review
- Drug repurposing-a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA).Frontiers in cardiovascular medicine · 2023Review
- Review
- Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.Medical sciences (Basel, Switzerland) · 2022Review
- Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme.International journal of molecular sciences · 2021Review
- Drug repurposing for COVID-19: Approaches, challenges and promising candidates.Pharmacology & therapeutics · 2021Review
- Network medicine framework for identifying drug-repurposing opportunities for COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing.Nature communications · 2021Article
- Review
- POLR3-Related Leukodystrophy: Exploring Potential Therapeutic Approaches.Frontiers in cellular neuroscience · 2020Article
- Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy.Frontiers in oncology · 2020Review
- Drug repurposing: progress, challenges and recommendations.Nature reviews. Drug discovery · 2019Review
- Pathway Network Analysis of Complex Diseases Based on Multiple Biological Networks.BioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One way to design a drug is to attempt to phenocopy a genetic variant that is known to have the desired effect. In general, drugs that are supported by genetic associations progress further in the development pipeline. However, the number of associations that are candidates for development into drugs is limited because many associations are in non-coding regions or difficult to target genes. Approaches that overlay information from pathway databases or biological networks can expand the potential target list. In cases where the initial variant is not targetable or there is no variant with the desired effect, this may reveal new means to target a disease. In this review, we discuss recent examples in the domain of pathway and network-based drug repositioning from genetic associations. We highlight important caveats and challenges for the field, and we discuss opportunities for further development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.